Miracle Drug Shelved:

Big Pharma Upset it Makes People ‘Too Healthy’ to Profit From

---

In a move that has shocked no one paying even the slightest bit of attention to modern healthcare, pharmaceutical companies have reportedly shelved a miracle drug capable of curing almost every known ailment. The drug, known scientifically as "Too Effective," was pulled from further development after Big Pharma executives discovered that its flaw was quite literally being too good at healing people.

“This is a disaster for the industry,” said one high-ranking official at a major pharmaceutical company, who asked to remain anonymous due to the obviously sinister undertones of the situation. “At first, we were excited. A drug that cures chronic diseases? We were thinking of the PR benefits, the Nobel Prize speeches, the celebrity endorsements. But then we ran the numbers and, well, it turns out there’s no market for people who are… you know, not sick anymore.”

The drug, which boasted the ability to cure everything from arthritis and asthma to broken bones and, somehow, emotional baggage, was touted as the most important medical advancement of the century. Early trials showed stunning success, with participants reporting miraculous recoveries within days. However, this success came with a fatal flaw: once cured, patients had the gall to stop spending money on further treatment.

Pharmaceutical executives, always eager to maintain a delicate balance between care and profit, were horrified at the implications. “We simply can’t monetize a cure-all,” said Marry Gnusk, CEO of Fizer Pharmaceuticals, during a press conference. “If patients no longer need long-term medication or recurring treatments, then how do we expect to stay in business? It’s irresponsible to market a drug that essentially makes people too healthy. We have investors to think about.”

Medical ethicists have, predictably, raised questions about the decision, noting that pulling the drug from production could, at a minimum, be considered “immoral” or, to use stronger language, “evil.” However, pharma insiders have been quick to shut down these critiques, claiming that the financial health of pharmaceutical companies must be prioritized if society is to continue enjoying the many benefits of high drug prices and confusing insurance policies.

“Let’s be realistic,” said an industry spokesperson. “Without us, who would fund all those glossy ads with people walking on beaches, or the 25-page pamphlets listing 400 side effects? There’s a reason our system works the way it does. If people get too healthy, we all lose.”

To make matters worse for the drug’s future, insiders revealed that attempts to find a way to make the miracle cure a monthly subscription service failed spectacularly. “We thought about turning it into something like a Netflix for health,” admitted the spokesperson. “But unfortunately, the drug’s effects were far too permanent. It’s hard to sell a recurring treatment plan when patients stop getting sick.”

Reports of potential black-market production of the drug have already surfaced, with underground healers attempting to distribute the cure at an affordable price. Big Pharma, in turn, has promised to crack down on these efforts, citing concerns that widespread distribution could “create a dangerous precedent” where people start expecting affordable, effective healthcare.

For now, the miracle drug will be locked away in the same dark vault that holds the cure for the common cold, affordable insulin, and the ability to actually understand hospital bills. As one pharmaceutical executive mused, “We can’t allow this kind of progress to undermine our carefully crafted business model. Who needs a world where people are healthy, anyway?”

Go to a Random Article